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week washout from 208 pg/ml to 316 pg/ml and then declined to 224RenaGelt, a nonabsorbed calcium- and aluminum-free phosphate
pg/ml at the end of the eight-week treatment period (P , 0.0001 vs.binder, lowers serum phosphorus and parathyroid hormone.
end of initial washout). After eight weeks of treatment, RenaGelt re-Background. This multicenter, open-label, dose-titration study as-
duced mean serum total cholesterol from 171.0 6 43.1 mg/dl to 145.0sessed the safety and efficacy of RenaGelt, a nonabsorbed calcium-
6 38.7 mg/dl (P , 0.0001) and mean serum low-density lipoproteinand aluminum-free phosphate binder, in lowering serum phosphorus.
cholesterol from 102.0 6 34.9 mg/dl to 75.6 6 29.4 mg/dl (P , 0.0001).Secondary outcomes were its effects on serum intact parathyroid hor-
High-density lipoprotein cholesterol, triglycerides, and serum albuminmone (iPTH) and serum lipids.
did not change.Methods. Phosphate binders were discontinued during a two-week
Conclusions. RenaGelt, a novel and calcium- plus aluminum-freewashout period. Patients whose serum phosphorus was more than 6.0
effective phosphate binder, can control serum phosphorus and reducemg/dl during washout were eligible for treatment. RenaGelt, at starting
the levels of PTH and cholesterol without inducing hypercalcemia ordoses of two, three, or four 440 mg capsules three times per day with
other side effects. Thus, this new phosphate binder may be effectivemeals, was administered to 172 hemodialysis patients for eight weeks.
in the treatment of renal osteodystrophy in uremic patients.RenaGelt could be increased by one capsule per meal every two weeks
as necessary to achieve serum phosphorus control. A second two-week
washout period followed.
Results. Mean serum phosphorus rose from 6.8 6 2.0 mg/dl at pre-
washout to 9.1 6 2.4 mg/dl at the end of the washout period. It then In patients with advanced renal failure, the hyperphos-
declined to 6.6 6 1.9 mg/dl by the end of the eight-week RenaGelt phatemia that develops is associated with severe compli-
treatment period (P , 0.0001). Serum phosphorus increased to 8.0 6
cations, including metastatic calcification, secondary hy-2.2 mg/dl at the end of the second washout period. The mean dose at
the end of RenaGelt treatment was 5.4 g per day. Eighty-four percent perparathyroidism, and osteitis fibrosa cystica, a bone
of the patients previously used calcium-based phosphate binders. As disease responsible for significant morbidity [1, 2]. Con-
expected, calcium declined during the initial washout period when
trol of dietary phosphate absorption in this population iscalcium-based phosphate binders were discontinued. Mean serum cal-
cium declined from 9.6 6 1.0 mg/dl at prewashout to 9.1 6 0.8 mg/dl essential for the prevention of these deleterious sequela.
after washout. It then increased to 9.4 6 0.9 mg/dl by the end of Usually, patients with end-stage renal disease (ESRD)
RenaGelt treatment. Median serum iPTH increased during the two-
are fed a minimum of 1.0 g of protein per kg of body
weight. Thus, it is difficult to restrict the amount of phos-
1 Members of the RenaGelt Study Group include the following: phorus in the diet to less than 1,000 mg per day. Because
Paul Bolin (Greenville, NC); Kenneth Boren (Mesa, AZ); K. Burke approximately 60% to 70% is absorbed, around 4,000 to
and Maureen Al Dillon (GelTex Pharmaceuticals, Inc., Waltham,
5,000 mg of phosphorus per week enters the extracellularMA); Douglass T. Domoto (St. Louis, MO); Thomas A. Golper (Little
Rock, AR); Fred Jones (Raleigh, NC); C.J. Kaupke (Orange, CA); fluid. Most hemodialysis patients are dialyzed three times
Robert Levinson (Hollywood, FL); Michael A. Marx (Little Rock, per week, and roughly 800 mg of phosphorus is removed
AR); William Mattern (Chapel Hill, NC); Mark S. Paller (Minneap-
per treatment [3]. Thus, most well-nourished patientsolis, MN); Maryella D. Sirmon (Mobile, AL); Eduardo Slatopolsky
(St. Louis, MO); Randall Stoltz, (Evansville, IN); John Wagner are in positive phosphorus balance. Consequently, ap-
(New Hyde Park, NY); Marc Weinberg (Providence, RI); Barry proximately 95% of dialysis patients use phosphate bind-Wilkes (Manhasset, NY); Duane Wombolt (Norfolk, VA); and James
ers to reduce dietary phosphorus absorption and achievevan Gelder (Hollywood, FL, USA).
serum phosphorus control. The most commonly usedKey words: dialysate, renal failure, osteodystrophy, uremia, hyperphos-
phatemia, bone disease. phosphate binders contain aluminum or calcium. Alumi-
num causes neurological, skeletal, and hematologic tox-Received for publication April 1, 1998
icities in ESRD patients [4–13], whereas calcium canand in revised form July 30, 1998
Accepted for publication August 5, 1998 lead to hypercalcemia in some patients as well as soft
tissue calcification [14–18]. Because these toxicities limit 1999 by the International Society of Nephrology
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Table 1. Dietary intake
Dietary intake parameter Mean sd
Phosphorus mg/day 774.6 291.5
Calcium mg/day 414.3 188.7
Vitamin D lg/day 5.9 3.9
Total energy kcal/day 1358.3 525.9
Total protein g/day 57.8 19.7
% Calories from protein 17.7 3.9
Total fat g/day 53.4 24.4
% Calories from fat 34.8 6.7
% Calories from carbohydrates 47.5 7.8
Iron mg/day 45.3 102.9
Sodium mg/day 2094.9 943.3
Potassium mg/day 1468.5 686.9
Total vitamin A lg/day 953.0 665.6
Total alpha-tocopherol equivalence mg/day 13.0 18.2
METHODS
Patients
The study included male and female hemodialysis pa-
tients 18 years of age or older treated a minimum of
three months with three times per week hemodialysis.
Inclusion criteria required stable dosage of an aluminum-
or calcium-based phosphate binder for at least one
month and, if the patient was on vitamin D replacementFig. 1. Structure of RenaGelt, cross-linked poly(allylamine hydrochlo-
ride). therapy, a stable dosage of vitamin D supplementation
for at least one month. Over the course of the study,
patients were prohibited from consuming antacids con-
taining aluminum or magnesium and were asked to avoid
utilization of phosphate binders, control of serum phos- intentional changes in diet. The vitamin D supplementa-
phorus in many patients is less than optimal. As a result, tion dose and regimen were maintained unless they
there is a need for a well-tolerated aluminum- and cal- needed to be adjusted for safety reasons. Table 1 depicts
cium-free phosphate binder. dietary intake parameters.
This multicenter, open-label, dose-titration study ex-
Study designamined the efficacy of RenaGelt, a nonabsorbed calci-
Patients were screened, and administration of calcium-um- and aluminum-free phosphate binder, in lowering
or aluminum-containing phosphate binders discontinuedserum phosphorus in hemodialysis patients. RenaGelt
during a two-week washout period (week 1 to 2). Patientsis a hydrogel of cross-linked poly (allylamine hydrochlo-
who developed hyperphosphatemia (serum phosphorusride), which is completely resistant to digestive degrada-
levels of more than 6.0 mg/dl) during this washout weretion and is not absorbed from the gastrointestinal tract
eligible to receive RenaGelt for eight weeks (weeks 3(Fig. 1). Partially protonated amines spaced one carbon
to 10). A second two-week washout period followedfrom the polymer backbone interact with phosphate
the end of RenaGelt treatment to establish that serumanions by ionic and hydrogen bonds. Preclinical and clini-
phosphorus control was due to RenaGelt treatmentcal studies have established the phosphate-binding ca-
(weeks 11 to 12).pacity of RenaGelt and its safety and efficacy in patients
RenaGelt was supplied as odorless, tasteless, hardwith ESRD [19–21].
gelatin capsules containing 440 mg RenaGelt. The start-
ing dose was two, three, or four capsules three times perObjective
day with meals based on washout serum phosphorus
The primary objectives of this study were to determine levels (Table 2). The RenaGelt dose could be increased
the efficacy of RenaGelt treatment in lowering serum one capsule per meal (three capsules per day) every two
phosphorus and the safety of RenaGelt in hemodialysis weeks as necessary to achieve serum phosphorus control.
patients. The secondary objectives were to assess the
Collection of blood samples and dietary intakeeffect of RenaGelt treatment on serum intact parathy-
roid hormone (PTH) and serum lipid profiles in hemodi- Blood samples were collected each week just prior to
dialysis after the longest interdialytic interval. All bloodalysis patients.
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Table 3. Common adverse eventsTable 2. Washout serum phosphorus ranges, the corresponding
RenaGel starting dose, and the number of patients starting
Adverse event %at each dose level
Pain 14.5Patients
Washout serum Capsules Diarrhea 12.8
Nausea 11.6phosphorus mg/dl t.i.d. N %
Dyspepsia 9.3
$6.0 to ,7.5 2 43 25 Chest pain 7.6
$7.5 to ,9.0 3 38 23 Headache 7.6





Hypotension 4.7samples were analyzed at SmithKline Beecham Clinical
Abdominal pain 4.1
Laboratories (Van Nuys, CA, USA) using standard clini- Puritus 4.1
Sepsis 3.5cal laboratory methods. iPTH was measured by an immu-
Flatulence 3.5nochemilumetric assay (ICMA assay) (upper limit of Gastrointestinal disorder 3.5
normal is 59 pg/ml). Dietary intake was assessed at the Hypocalcemia 3.5
Asthenia 2.9University of Massachusetts Medical Center (Worcester,
Hypertension 2.9
MA, USA) using the 24-hour recall method [22]. The Anorexia 2.9
Hypervolemia 2.9subjects were called at three random times during each
Peripheral edema 2.9of the baseline, washout, and treatment phases. Thus,
Dizziness 2.9
each subject was interviewed nine times during the 12 Insomnia 2.9
Pneumonia 2.9weeks of the study. The calls were scheduled to include
Fever 2.3one dialysis day, one nondialysis day, and a weekend Arterial anomaly 2.3
Eructation 2.3day for each of the study periods.
Myalgia 2.3The protocol was approved by the Human Research
Cough increased 2.3
Committee at each institution, and informed consent was
obtained from each patient.
Table 4. Patient characteristicsStatistical methods
CharacteristicWilcoxon signed rank tests were used to assess changes
in dietary intake levels and serum concentrations. A Gender
Male 64%linear regression model was used to identify factors asso-
Female 36%
ciated with changes in serum phosphorus. Spearman Race
African American 52%rank correlation was used to examine the relationship
Caucasian 34%between the change in serum phosphorus, calcium, and
Hispanic 13%
iPTH. Chi-squared tests were used to test RenaGelt Other 2%
Age yearsdose level group differences for adverse effects, and
Mean (range) 53 (18 to 86)Kruskal–Wallis tests were used to test RenaGelt dose Weight g
Mean (range) 79.8 (25 to 175)level group differences for laboratory data. All statistical
Prior phosphate binderanalyses were based on two-tailed hypothesis tests, with
Calcium acetate 48%
a significance level of P . 0.05. A last-observation carry- Calcium carbonate 36%






Patients Polycystic kidney disease 5%
Other 28%A total of 172 patients qualified for RenaGelt treat-
ment. Post-baseline serum phosphorus data were not
available for four patients, and consequently efficacy
analyses were conducted on 168 patients. In total, 144 an adverse event (Table 3); one patient died of a cardiac
patients completed the eight-week treatment period. arrest; one patient discontinued due to noncompliance;
Twenty-four patients did not complete the eight-week three patients withdrew consent; one patient was lost to
follow-up; and three patients discontinued for “othertreatment period: 15 patients were discontinued due to
Slatopolsky et al: RenaGelt lowers serum phosphorus and PTH302
Fig. 2. Effect of RenaGelt on serum phos-
phorus. During the treatment period with
RenaGel the decrease in serum phosphorus
9.1 6 2.4 to 6.6 6 1.9 mg/dl was statistically
significant (P . 0.0001).
reasons.” Table 4 summarizes the demographic charac- the study. Mean serum calcium levels decreased from
9.6 6 1.0 mg/dl at prewashout to 9.1 6 0.8 mg/dl afterteristics of the patient population.
washout. Mean serum calcium levels increased to 9.4 6
Dosage, compliance, and dietary intake 0.9 mg/dl following eight weeks of RenaGelt treatment
(P , 0.0001). After a second two-week washout, meanThe mean starting daily dose of RenaGelt was 4.0 g
serum calcium significantly decreased to 9.2 6 0.9 mg/dlper day, whereas the mean daily dose at the end of the
(P 5 0.0132). Changes in serum calcium were similareight-week treatment period was 5.4 g per day. The mean
between vitamin D users and nonusers.percentage compliance with RenaGelt was 85.1% by
The mean calcium–phosphate product (Fig. 4) in-pill count. No significant changes in dietary phosphorus
creased from 64.7 to 82.1 mg2/dl2 at the end of the wash-and calcium intake occurred during the study.
out period. Mean calcium–phosphorus product decreased
to 59.8 mg2/dl2 after eight weeks of RenaGelt treatment.Serum phosphorus, calcium, and intact
Subsequently, after discontinuing RenaGelt, mean se-parathyroid hormone
rum calcium–phosphate product increased to 74 mg/dl.Serum phosphorus, calcium, and intact parathyroid
Median serum iPTH levels over the course of the studyhormone (iPTH) levels significantly changed during Rena-
are displayed in Figure 5. The median values were chosenGel treatment. Figure 2 displays mean serum phosphorus
for display because the distribution of iPTH data waslevels throughout the study. Mean serum phosphorus lev-
skewed by a subset of patients with extreme elevationsels increased from 6.8 6 2.0 mg/dl at prewashout to 9.1 6
in iPTH. Median serum iPTH levels increased during2.4 mg/dl after washout. Upon initiation of RenaGelt
the washout period from 208 pg/ml to 316 pg/ml. Upon
treatment, serum phosphorus levels declined immedi- initiation of RenaGelt treatment, median serum iPTH
ately and continued declining until the cessation of treat- levels declined immediately, reaching 224 pg/ml by the
ment. Mean serum phosphorus decreased from 9.1 6 end of the eight-week treatment period (P , 0.0001).
2.4 mg/dl to 6.6 6 1.9 mg/dl during eight weeks of treat- After two weeks of a second washout, median serum
ment (P , 0.0001). After the post-treatment washout, iPTH increased to 307 pg/ml (P , 0.0001). RenaGelt
mean serum phosphorus significantly increased to 8.0 6 treatment lowered median iPTH levels in both vitamin
2.2 mg/dl (P , 0.0001), establishing that serum phospho- D users and nonusers. There was no significant difference
rus control was due to RenaGelt treatment. RenaGelt in PTH levels between the prewashout measurement and
dose was a significant predictor of the decrease in serum the end of the treatment measurement (P 5 0.1567).
phosphorus levels. RenaGelt treatment provided compa-
Serum lipidsrable reductions in serum phosphorus for both vitamin D
users (2.6 6 2.5 mg/dl) and nonusers (2.4 6 2.0 mg/dl). RenaGelt treatment significantly reduced mean se-
rum total cholesterol (Fig. 6) from 171.0 6 43.1 to 145.0Figure 3 displays mean serum calcium levels during
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Fig. 3. Effect of RenaGelt on serum calcium.
Fig. 4. Effect of RenaGelt on Ca 3 P
product.
6 38.7 mg/dl after eight weeks of treatment (P , 0.0001), that adverse effects were not related to RenaGelt treat-
primarily because of a decrease in mean low-density ment. There were no clinically significant changes in
lipoprotein (LDL) from 102.0 6 34.9 mg/dl to 75.6 6 29.4 laboratory parameters, including serum chemistries, he-
mg/dl (P , 0.0001; Fig. 7). Mean high-density lipoprotein patic function tests, hematologic parameters, coagulation
cholesterol and triglycerides did not change during the tests, or serum vitamin levels (A-D and E) over the
study. This represents a mean decrease in LDL choles- course of the study.
terol of 15.1% in patients with baseline LDL cholesterol
less than 100 mg/dl, and a 29% decrease in patients with
DISCUSSIONbaseline LDL cholesterol equal to or greater than 100
The efficacy of currently available calcium- or alumi-mg/dl. No change was observed in serum albumin in
num-containing phosphate binders is constrained by theeither group during RenaGelt treatment.
side effects associated with the absorption of calcium
Safety and aluminum. This study explored the use of RenaGelt,
a calcium- and aluminum-free polymeric phosphateRenaGelt was well tolerated. There were no differ-
ences across the RenaGelt dose level groups, suggesting binder, in lowering serum phosphorus in hemodialysis
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Fig. 5. Effect of RenaGelt on serum para-
thyroid hormone (PTH). At the end of the
2 week treatment, the decrease in PTH was
statistically significant (P , 0.0001). After
RenaGel was discontinued there was a sig-
nificant increase in the levels of serum PTH
(P , 0.0001).
Fig. 6. Effect of RenaGelt on serum total
cholesterol.
patients. The primary objectives of this study were to phorus significantly decreased from 9.1 mg/dl to 6.6 mg/
dl (P , 0.0001) during eight weeks of RenaGelt treat-determine the efficacy of RenaGelt treatment in low-
ering serum phosphorus and the safety of RenaGelt ment and significantly increased after a two-week post-
treatment washout (P , 0.0001), establishing that thein hemodialysis patients. Secondary objectives were to
determine the effect of RenaGelt on serum iPTH and observed lowering of serum phosphorus was due to Re-
naGelt treatment.lipid profiles.
RenaGelt significantly reduced serum phosphorus in The onset of RenaGelt efficacy was rapid. The initial
prescribed RenaGelt dose of two, three, or four capsulesthis hemodialysis patient population. Mean serum phos-
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Fig. 7. Effect of RenaGelt on serum low
density lipoprotein (LDL). The decrease in
LDL was highly statistically significant (P ,
0.0001).
three times a day with meals substantially reduced serum humans, the control of serum phosphorus is of the utmost
importance to prevent increased release of PTH fromphosphorus levels within two weeks. Titration of the
drug after two and four weeks of treatment led to further the parathyroid cells. Several investigators were unable
to demonstrate apoptosis of the parathyroid glands inreductions; mean serum phosphorus levels returned to
prewashout levels by the sixth week of RenaGelt treat- uremic rats treated with 1,25(OH)2D3, low-phosphorus
diet, or calcimemtic drugs [25, 33, 34]. Hence, it seemsment. Based on this study, the anticipated average clini-
cal dose of 5.4 g/day will provide serum phosphorus likely that when patients develop severe hyperplasia of
the parathyroid glands, although PTH secretion may becontrol comparable to that achieved with currently avail-
able calcium-and/or aluminum-based phosphate binders. temporarily controlled by the administration of a low-
phosphorus diet, there remains a potential for rapid andGreater serum phosphorus reduction was readily attain-
able with higher doses if escalation was warranted by increased secretion of PTH under the right circum-
stances (such as hyperphosphatemia and/or hypocal-patient response.
Several investigators have demonstrated in experi- cemia). Recently, Kates et al showed that serum phos-
phorus is independently associated with serum PTH inmental animals [23–27] and in vitro studies that phospho-
rus levels per se [independent of serum ionized calcium patients with chronic renal failure [35]. These investiga-
tors performed a cross-sectional analysis of 84 patientsand 1,25(OH)2D3] increased the synthesis and secretion
of PTH. Similar results were shown in uremic patients with varying levels of chronic renal failure. Using step-
wise regression analysis after adjusting for multiple com-[28–30]. Moreover, phosphorus also plays an important
role in the development of parathyroid cell hyperplasia parisons, they found that serum phosphorus correlated
directly with serum PTH (r 5 0.62, P , 0.01) in patients[25, 26, 31, 32]. Recently, Takahashi et al [33] demon-
strated in uremic rats with severe secondary hyperpara- with mild to moderate chronic renal failure (creatinine #
3.0 mg/dl).thyroidism and hyperplasia of the parathyroid glands
that when the rats were fed a low-phosphorus diet, the Because calcium acetate and calcium carbonate were
discontinued as phosphate binders during the washoutlevels of PTH returned to normal. However, the size of
the parathyroid glands did not change. Moreover, when period, the observed decline in mean serum calcium in
the initial washout period was anticipated. RenaGeltintracellular PTH was measured in the parathyroid
glands, PTH was the same before or after the administra- treatment moderately increased serum calcium levels
from 9.1 mg/dl to 9.4 mg/dl after eight weeks of treatmenttion of a low-phosphorus diet. In other words, it is possi-
ble to have hyperplasia of the parathyroid glands without (P 5 0.0001). Several factors could explain this increase
in mean serum calcium. First, lowering the serum phos-secondary hyperparathyroidism.
If we can extrapolate these results obtained in rats to phorus with RenaGelt could have corrected the high
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calcium phosphorus product leading to less precipitation by 20%. These changes in the lipid profile may lead to
of serum calcium [36]. Second, lowering serum phospho- important reductions in morbidity in dialysis patients
rus may have improved the calcemic response to PTH [Chertow GM, Burke SK, Dillon M, Slatopolsky E.,
[37]. Third, intestinal phosphate binding by RenaGelt for the RenaGelt Study Group: A long-term study of the
could have increased the intestinal absorption of calcium. effectiveness of sevelamer hydrochloride (RenaGelt) in
Dietary calcium absorption is normally limited by precip- hemodialysis patients. (abstract) J Am Soc Nephrol
itation in the intestine with anions such as phosphate. 9:552A, 1998]
Notably, despite this increase in serum calcium, mean
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levels. The lower serum calcium concentrations might This work was supported by a grant provided by Gel-Tex Pharma-
reduce the incidence of hypercalcemia observed during ceuticals. We thank Sue Viviano for assistance in the preparation of
the manuscript.treatment with calcium-based phosphate binders [15–
17]. This is of utmost importance in patients with severe
Reprint requests to: Eduardo Slatopolsky, M.D., Washington Univer-
hyperparathyroidism (PTH of more than 1,000 pg/ml) sity School of Medicine, 660 South Euclid Avenue, Box 8129, St. Louis,
MO 63110, USA.because large doses of calcitriol are necessary to suppress
E-mail: eslatopo@imgate.wustl.eduthe synthesis and secretion of PTH, and the administra-
tion of large doses of calcitriol are usually associated
REFERENCESwith increases in the levels of serum calcium. Because
1. Coburn JW, Slatopolsky E: Vitamin D, parathyroid hormoneRenaGelt is calcium free, physicians should be able to
and renal osteodystrophy, in The Kidney (4th ed), edited by Bren-prescribe calcitriol and evoke less frequent episodes of
ner BM, Rector FC Jr, Philadelphia, Saunders, 1991, pp 2036–2122
hypercalcemia. 2. Delmez J, Slatopolsky E: Hyperphosphatemia: Its consequences
Serum iPTH levels significantly decreased during and treatment in patients with chronic renal disease. Am J Kidney
Dis 4:303–317, 1992RenaGelt treatment. This decline was anticipated be-
3. Hou SH, Zhao J, Ellman CF, Hu J, Griffin Z, Spiegel DM,cause serum calcium and phosphorus are known to regu- Bourdeau JE: Calcium and phosphorus fluxes during hemodialysis
late PTH secretion [1]. As expected, the increase in se- with low calcium dialysate. Am J Kidney Dis 18:217–224, 1991
4. Alfrey AC, Le Gendre GR, Kaehney WD: The dialysis encepha-rum phosphorus and the decrease in serum calcium
lopathy syndrome: Possible aluminum intoxication. N Engl J Medduring the washout periods prompted a corresponding 315:157–161, 1976
increase in iPTH. 5. Berlyne GM, Ben-Ari J, Pest D, Weinberger J, Stern M, Gil-
more GR, Levine R: Hyperaluminaemia from aluminum resins inRenaGelt treatment moderately reduced both serum
renal failure. Lancet 2:494–496, 1970total cholesterol and LDL cholesterol. RenaGelt treat-
6. Felsenfeld AJ, Gutman RA, Llach F, Harrelson JM: Osteoma-
ment had no effect on high-density lipoprotein choles- lacia in chronic renal failure; a syndrome previously reported only
with maintenance dialysis. Am J Nephrol 2:147–154, 1982terol and triglycerides. This cholesterol-lowering effect
7. Griswold WR, Reznik V, Mendoza SA, Trauner D, Alfreyof RenaGelt was most apparent in patients with LDL
AC: Accumulation of aluminum in a nondialyzed uremic child
cholesterol of 100 mg/dl or greater at baseline and may receiving aluminum hydroxide. Pediatrics 71:56–58, 1983
8. Kaye M: Oral aluminum toxicity in a nondialyzed patient withbe beneficial in some patients. Cardiovascular events,
renal failure. Clin Nephrol 20:208–211, 1983mainly related to atherosclerosis, are the most common
9. Salusky IB, Coburn JW, Paunier L, Sherrard DJ, Fine RN:
cause of death in dialysis patients [38, 39]. Longer term Role of aluminum hydroxide in raising serum aluminum levels in
studies of lipid lowering in dialysis patients would be children undergoing continuous ambulatory peritoneal dialysis. J
Pediatr 105:717–720, 1984required to confirm this potential benefit.
10. Sherrard DJ, Ott SM, Maloney NA, Andress D, Coburn JW:In summary, RenaGelt, a nonabsorbed aluminum- Uremic osteodystrophy: Classification, cause and treatment, in
and calcium-free phosphate binder, safely and effectively Proceedings of the Symposium on Clinical Disorders of Bone and
Mineral Metabolism, edited by Frame B, Potts JT, Amsterdam,reduced serum phosphorus in hemodialysis patients.
Excerpta Medica, 1984, pp 254–258RenaGelt was well tolerated, significantly decreased se- 11. Malluche HH, Smith AJ, Abreo K, Faugere M-C: The use of
rum intact PTH, and maintained serum calcium below deferoxamine in the management of aluminum accumulation in
bone in patients with renal failure. N Engl J Med 311:140–144,prewashout levels in hemodialysis patients. It also re-
1984duced total and LDL cholesterol. Thus, this new phos- 12. Hodsman AB, Sherrard DJ, Alfrey AC, Ott S, Brickman AS,
phate binder may greatly improve the treatment of sec- Miller NL, Maloney NA, Coburn JW: Bone aluminum and histo-
morphometric features of renal osteodystrophy. J Clin Endocrinolondary hyperparathyroidism in uremic patients.
Metab 54:539–546, 1982
13. Ott SM, Maloney NA, Coburn JW, Alfrey C, Sherrard DJ:
The prevalence of bone aluminum in renal osteodystrophy andNOTE ADDED IN PROOF
its relation to the response to calcitriol therapy. N Engl J Med
307:709–713, 1982During the American Society of Nephrology meeting
14. Moriniere PH, Russel A, Tahiri Y, Fremont JF, Maurel G,in Philadelphia, October 26, 1998, Dr. G.M. Chertow et
Jaudon MC, Gueris J, Fournier A: Substitution of aluminum
al demonstrated that long-term studies with RenaGelt hydroxide by high doses of calcium carbonate in patients on chronic
hemodialysis: Disappearance of hyperaluminemia and equal con-not only decreased LDL by 30%, but increased HDL
Slatopolsky et al: RenaGelt lowers serum phosphorus and PTH 307
trol of hyperparathyroidism. Proc Eur Dial Transplant Assoc of calcium, phosphate and vitamin D. J Clin Invest 96:1786–1793,
199519:784–787, 1982
26. Slatopolsky E, Finch J, Denda M, Ritter C, Zhong M, Dusso15. Fournier A, Moriniere P, Sebert JL, Dhissi H, Atik A, Leflon
A, MacDonald P, Brown AJ: Phosphorus restriction preventsP, Renaud H, Gueris J, Gregoire I, Idrissi A, Garabedian M:
parathyroid gland growth: High phosphorus directly stimulatesCalcium carbonate, an aluminum-free agent for control of hyper-
PTH secretion in vitro. J Clin Invest 97:2534–2540, 1996phosphatemia, hypocalcemia and hyperparathyroidism. Kidney Int
27. Almaden Y, Canalejo A, Hernandez A, Ballesters E, Garcia-29:S114–S119, 1986
Navarro S, Torres A, Rodriguez M: Direct effect of phosphorus16. Salusky IB, Coburn JW, Foley J, Nelson P, Fine RN: Oral
on PTH secretion from whole rat parathyroid glands in vitro. Jcalcium carbonate as a phosphate-binding agent in children on
Bone Miner Res 11:970–976, 1996dialysis: Effect on plasma aluminum levels. J Pediatr 108:767–770, 28. Lucas PA, Brown RC, Woodhead JS, Coles GA: 1,25-Dihydrox-
1986 ycholecalciferol and parathyroid hormone in advanced chronic
17. Slatopolsky E, Weerts C, Lopez-Hilker J, Norwood K, Zink renal failure: Effect of simultaneous protein and phosphorus re-
M, Windus D, Delmez J: Calcium carbonate as a phosphate- striction. Clin Nephrol 25:7–10, 1986
binder in patients with chronic renal failure undergoing dialysis. 29. Schaefer K, Erley CM, von Herrath D, Stein G: Calcium salts
N Engl J Med 315:157–161, 1986 of ketoacids as a new treatment strategy for uremic hyperphospha-
18. Hercz G, Kraut JA, Andress DA, Howard N, Roberts C, Shi- temia. Kidney Int 36:S136–S139, 1989
30. Aparicio M, Combe C, Lafage MH, DePecigout V, Potaux L,naberger JH, Sherrard DF, Coburn JW: Use of calcium carbon-
Bourchet JL: In advanced renal failure, dietary phosphorus re-ate as a phosphate-binder in dialysis patients. Miner Electrolyte
striction reverses hyperparathyroidism independent of the levelsMetab 12:314–319, 1986
of calcitriol. Nephron 63:122–123, 199419. Rosenbaum DP, Holmes-Farley WH, Manderville M, Gold-
31. Wang O, Palnitkar S, Parffitt AM: Parathyroid cell proliferationberg DI: Effects of RenaGelt, a nonabsorbable, cross-linked, poly-
in the rat. Effect of age and phosphate administration and recovery.meric phosphate binder on urinary phosphorus excretion in rats.
Endocrinology 137:4558–4562, 1996Nephrol Dial Transplant 11:808–812, 1996
32. Parfitt AM: The hyperparathyroidism of chronic renal failure: A20. Burke SK, Slatopolsky E, Goldberg DI: RenaGelt, a novel disorder of growth. Kidney Int 52:3–9, 1997
calcium-and aluminum-free phosphate binder, inhibits phosphate 33. Takahashi F, Finch J, Brown AJ, Slatopolsky E: The effects of
absorption in normal volunteers. Nephrol Dial Transplant 12:1640– a low phosphorus diet on the section of PTH in establishing diffuse
1644, 1997 parathyroid hyperplasia. (abstract) J Am Soc Nephrol 8:508A, 1997
21. Chertow GM, Burke SK, Lazarus JM, Stenzel KH, Wombolt 34. Wada M, Furuya Y, Sakiyama J, Kobayashi N, Miayata S, Ishii
D, Goldberg D, Bonventre J, Slatopolsky E: Poly [alkylamine H, Nagano N: The calcimimetic compound NPS R-68 suppresses
hydrochloride] RenalGelt: A noncalcemic phosphate binder for parathyroid cell proliferation in rats with renal insufficiency: Con-
the treatment of hyperphosphatemia in chronic renal failure. Am trol of parathyroid cell growth via a calcium receptor. J Clin Invest
100:2877–2983, 1997J Kidney Dis 1:66–71, 1997
35. Kates DM, Sherrard DJ, Andress DL: Evidence that serum22. Posner BM, Borman CL, Morgan JL, Borden WS, Ohls JG:
phosphate is independently associated with serum PTH in patientsThe validity of a telephone-administered 24-hour dietary recall
with chronic renal failure. Am J Kidney Dis 30:809–813, 1997methodology. Am J Clin Nutr 36:546–553, 1982
36. Katz A, Hampers CL, Merrill JP: Secondary hyperparathyroid-23. Lopez-Hilker SA, Dusso A, Rapp N, Martin KJ, Slatopolsky
ism and renal osteodystrophy in chronic renal failure. MedicineE: Phosphorus restriction reverses hyperparathyroidism in uremia
48:333–374, 1969independent of changes in calcium and calcitriol. Am J Physiol
37. Rodriguez M, Martin-Malo A, Martinez MD, Torres A,259:F432–F437, 1993 Felsenfeld AJ, Llac F: Calcemic response to parathyroid hor-
24. Yi H, Fukagawa M, Yamamoto H, Kumagai M, Watanabe T, mone in renal failure: Role of phosphorus and its effects on
Kurokawa K: Prevention of enhanced parathyroid hormone secre- calcitriol. Kidney Int 40:1055–1062, 1991
tion, synthesis and hyperplasia by mold dietary phosphorus restric- 38. Bomer J, Stroheck E, Goerich J, Babner M, Zuna I: Arterioscle-
tion in early chronic renal failure in rats: Possible direct role of rosis in dialysis patients. Int J Artif Organs 19:638–644, 1996
phosphorus. Nephron 70:242–248, 1995 39. United States Renal Data System: USRDS 1997 Annual Report.
25. Naveh-Many T, Rahamimo R, Livni N, Silver J: Parathyroid cell National Institutes of Health, National Institute of Diabetes and
Digestive and Kidney Disease, Bethesda, MD, 1997, 93 pp.proliferation in normal and chronic renal failure rats: The effects
